Magnetic Resonance-Guided Prostate Biopsy.
Magnetic Resonance-Guided Prostate Biopsy. Magn Reson Imaging Clin N Am. 2015 Nov;23(4):621-31 Authors: Dianat SS, Carter HB, Macura KJ Abstract The optimal strategy for prostate cancer diagnosis is to avoid overdiagnosis, defined as diagnosis of clinically insignificant disease, and undersampling of the gland, which leads to missing clinically significant disease. Targeted prostate biopsy is a potential solution for decreasing the rate of both overdiagnosis and undersampling of prostate cancer. We focus here on different techniques for targeting prostate lesions identified on multiparametric MR imaging and review different clinical settings in which MR imaging-targeted prostate biopsies are performed. PMID: 26499279 [PubMed - in process]
In this study, first we determined toxic doses of this complex on NIH/3T3 normal fibroblast cells, SPC212 mesothelioma and ascertained anti-proliferative, apoptotic and morphological effects of these newly synthesized compounds on DU145 prostate cancer cells through cytotoxic and microscopic methods. A novel Copper(II)/1-(4-(trifluoromethyl)benzyl)-1H-benzimidazole/2,2’-bipyridyl complex, was synthesized, and mainly characterized by single crystal x-ray diffraction analysis. Anti-proliferative effect of copper(II) complex was gauged by MTT. Its morphological effect was examined by microscope analysis. Besides, immuno...
ConclusionsBoth PASS-RCs improved the balance between detecting reclassification and performing surveillance biopsies by reducing unnecessary biopsies. Recalibration to the local setting will increase their clinical usefulness and is therefore required before implementation.Patient summaryUnnecessary prostate biopsies while on active surveillance (AS) should be avoided as much as possible. The ability of two calculators to selectively identify men at risk of progression was tested in a large cohort of men with low-risk prostate cancer on AS. The calculators were able to prevent unnecessary biopsies in some men. Usefulness ...
Prostate Cancer UK says that two-fifths of urology cancer nurse specialists are approaching retirement or plan to leave the job in the next decade.
Conclusions: Fluoroscopy and 3D CT image-guided interstitial brachytherapy is feasible and appears to be a suitable treatment technique for patients with clinically localized prostate cancer after previous rectal resection and external beam radiation therapy. PMID: 31435432 [PubMed]
Conclusions: Whole-gland salvage BT is an effective treatment with an acceptable toxicity profile. The pathology findings from RARP imply that there is a room for improvement in diagnoses made by MRI in the pre-salvage setting. PMID: 31435426 [PubMed]
Conclusions: During the first 4 years after BT, more than half of patients maintained an IIEF-5> 16, and EF results remained stable. Severe erectile dysfunction (ED) was very rare. PMID: 31435425 [PubMed]
For men with localized prostate cancer (CaP), radical prostatectomy (RP) as well as radiotherapy (RT) was associated with lower incidences of progression and metastases than was active monitoring.1 Meanwhile, prospective trial showed these patients with a long life expectancy would benefit from surgical intervention with a mean gain of almost 3-year of life.2 Unfortunately, when localized CaP progressed to incurable metastatic disease ancestral subclones and stromal micro-environment evolved dynamically in space and time following principles of selective evolution, underpinning important emergent features such as therapeut...
Retrospective evaluations of the treatment of the primary tumor in the setting of metastatic hormone sensitive prostate cancer (mHSPC) are prevalent in the recent literature. The majority of these reports have favored the addition of local therapy1 and form the hypothesis generating support for recently completed and ongoing prospective randomized studies.2,3 Interestingly, in the present retrospective study, cancer-specific survival was not improved with local therapy. This is intriguing since the patients were subject to similar selection biases present in other retrospective reviews favoring local therapy.
The accuracy of magnetic resonance imaging (MRI) for prostate cancer detection has been demonstrated in multiple studies, but the interpretation of prostate MRI can be quite challenging. In particular, changes caused by aging (ie, hyperplasia) or by pathologic conditions such as inflammation or cancer can lead to a nearly singular appearance on MRI for each prostate. Additionally, the lack of robust standardization across MRI scanners hampers the adoption of quantitative parameters for imaging analysis.
The treatment options for metastatic prostate cancer have increased dramatically over the past decade, including novel hormonal therapies, chemotherapies, and radiopharmaceuticals. The administration of myelosuppressive chemotherapies has generally been supervised by medical oncologists in the United States. The oversight of oral agents such as abiraterone + prednisone (abi) and enzalutamide (enza) has been less well defined. This issue of the Gold Journal describes the increasing role of urologists in prescribing these agents.